PATENT 101 seminar is postponed to September - stay tuned

Date: June 9, 2016 @ 6:00 pm – @ 9:00 pm
Location: 1633 Bayshore Hwy, suite 280, Burlingame 94010

PATENT 101 seminar is postponed to September - stay tuned (this information is updated on June 1, 2016)

If you have any questions, please email icc@cabsweb.org

If you are interested in attending this seminar, please register online.  Registration is free.

Meanwhile, when you register, please let us know the area(s) of patent law you are interested in learning more about as well as the specific question you may have so we can try to explain it during the seminar.

If you have trouble to register, please email icc@cabsweb.org

Agenda:

6:00-6:20 pm networking

6:20-7:00 pm presentation

7:00-8:30 pm questions and answers

8:30-9:00 pm networking

At this patent seminar, two patent attorneys, Dr. Lei Fang and Mr. Jigang Jin, will share with you what patent issues you may face and how to address these issues when you start your new biotech company. 

They will use the hypothetical example below to introduce and discuss the following basic patent law and license issues in the bio-pharma life sciences fields:

-                     When and where should a patent application be filed?

-                     What can be patented (patentable subject matter & types of patent applications)?

-                     What are the basic criteria for granting a patent (patentability requirements)?

-                     What are the timeline and cost for obtaining a patent?

-                     Ownership vs. inventorship of a patent

-                     Technology transferring and licensing (exclusive vs. nonexclusive; terms, sublicense, payments, fields and territories of license, etc.)

Hypothetical example:

Dan is a scientist and entrepreneur, starting a new biotech company XYZ, Inc. which will develop certain therapeutics for cancer treatment.  One of the technologies that will be used to develop those therapeutics is protected under a third party’s patents.  To avoid potential infringement of these patents, what and how should Dan do before he can even use the third-party’s patented technology in the development of his own company’s therapeutics?

Also, Dan has conceived some ideas on molecular structures of certain lead products for the therapeutics he is going to develop, as well as certain unique methods of making and/or using these potential lead products for preventing and/or treating certain disease conditions.  Some of these ideas have been tested experimentally in the laboratory animals and cell cultures. However, no actual clinical or human studies has been conducted at this point. In addition, more than one year ago, Dan has published a paper describing certain researches he had done which may lay down the groundwork for the development of these therapeutics.  When, what, and how can Dan do to protect his own developments of the lead therapeutics, as well as the methods of making and/or using these therapeutics?

Presenters:

LEI FANG, Ph.D., Patent Attorney

Dr. Lei Fang advises domestic and international clients on a wide range of intellectual property matters. She helps clients identify key intellectual property and develop portfolio protection strategies. Lei prosecutes patent and trademark applications before the US Patent & Trademark Office, and counsels clients and provides legal opinions on patentability, validity, non-infringement, and freedom-to-operate issues primarily in the life sciences sector related to biotechnology, pharmaceuticals, and medical devices inventions. Lei also helps clients on technology transferring and licensing and FDA regulatory reviews for drugs and medical devices.  She also conducts intellectual property due diligence and provides product clearance opinions and development strategies. Her experiences in patent litigation include participating and providing technical support in the Hatch-Waxman ANDA (Paragraph IV) patent litigation involving generic pharmaceuticals, and managing International Trade Commission Section 337 investigations and related district and appellate court cases involving Chinese companies. Lei also helps clients to obtain a copyright registration before the US Copyright Office.

For more than a decade, Lei has worked with clients ranging from multinational corporations, to early stage entrepreneurial companies, to nonprofit university and science research institutes.  Her extensive knowledge on intellectual property related matters in the biotechnology, pharmaceutical, medical device, and life sciences industries have led to many speaking engagements for her.

With her native Chinese background, Lei speaks and writes fluent Chinese and offers clients a unique combination of legal knowledge, advanced scientific and technical training, and an intimate understanding of the Asian marketplace. Lei is actively involved in many Asian-American organizations, many of which she serves as a legal counsel.  She also represents multiple Chinese companies in various corporate and intellectual property matters in the United States.

Before starting JIN & FANG LLP, Lei worked as a patent attorney at a few prestigious US firms (e.g., Sutherland Asbill & Brennan LLP and Troutman Sander LLP).  Prior to launching her legal career, she had a postdoctoral training at Harvard Medical School/Brigham Women’s Hospital. She also worked as a research scientist at a biotech/pharmaceutical company in Cambridge, MA.

JIGANG JIN, Patent Attorney

Jigang’s practice focuses on patent prosecution, counseling, and litigation in industries including telecommunication, consumer electronics, semiconductor, computer software and hardware, wireless and mobile, Internet, robot, artificial intelligence, and medical device. His deep technical knowledge and experience allow him to quickly understand clients' technology and bring optimal legal solutions for client's issues.

Jigang has helped both well-established companies as well as startup companies obtain patents.  In addition, he has litigated cases in U.S. district courts and participated in International Trade Commission investigations. Before starting JIN & FANG LLP, Jigang worked as a patent attorney at Ropes & Gray LLP, Skadden, Arps, Slate, Meagher & Flom LLP, Cooley LLP, Blakely Sokoloff Taylor & Zafman LLP.
Prior to attending law school, Jigang worked as a software engineer designing and developing distributed and web-based software systems for major insurance companies. He also has experience working on various software system integration projects.